December 08, 2020
1 min watch
Mehta-Shah N, et al. Abstract 41. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Barta reports consulting for Monsanto; research funding from Seattle Genetics; and receiving honoraria from Acrotech, Atara, Janssen, Pfizer and Seattle Genetics.
Allogeneic hematopoietic transplantation yielded durable disease control for patients with relapsed or refractory or otherwise high-risk T-cell lymphoma, according to a presentation at ASH Annual Meeting and Exposition.
The study, which is the largest retrospective analysis of HCT in T-cell lymphoma, included 500 patients across 12 centers with a variety of T-cell lymphomas, Stefan K. Barta, MD, MS, MRCP, director of the T-Cell Lymphoma Program at Penn Medicine, told Healio in a video interview.
The treatment-related mortality rate was 11.2%, which Barta said is “pretty amazing.” The 2-year OS and PFS rate following allogeneic hematopoietic transplantation were 59.1% and 45.8%, and the 5-year OS and PFS rate were 50.8% (95%CI, 46.1-55.3%) and 39.4%, according to the abstract.
“Over the last 2 decades, we’ve been much better in A, typing our patients and finding better donors and B, managing infections and graph host disease so supportive care has improved,” Barta said. “This [study] underpins the allogenic transplant as a very reasonable option for patients specifically who achieved a complete response to salvage therapy. It provides us great information and numbers to discuss this option with our patients – in that respect, it’s a very important study.”